For research use only. Products are supplied strictly for laboratory and research purposes and are not intended for human consumption.
- Batch tested
- COA available
- Research use only
Dual agonist
Tirzepatide
Dual incretin receptor agonist sequence used in GIP and GLP-1 receptor research across in vitro metabolic models.
Strength
Quantity
15% off your first order with code FIRST15
Bundle & save
Fast UK dispatch
Dispatch information shown at checkout
Tracked UK delivery
Available delivery options are shown at checkout
Protected shipping
Please see our Shipping Policy for full details.
Secure checkout
More ways to shop
Build a Box
Create a personalised research box from selected Amino Peppers compounds.
Verified test results
Every batch, independently documented.
Review the testing information and certificate available for the selected product batch.
ILS Laboratories
Certificate of Analysis
99.61%
Purity
- Lot
- APTIRZ02
- Tested
- 12 Jun 2026
- Label claim
- 10mg vial
- Measured
- 10mg vial
Full QC panel
8 results reported
Appearance
Visual
White lyophilised cake
PassPurity
HPLC-UV, 214nm
99.61%
PassNet peptide content
Nitrogen determination
Conforms
PassIdentity
LC-MS (ESI+)
Confirmed
PassBacterial endotoxin
LAL kinetic chromogenic
< 0.05 EU/mg
PassHeavy metals
ICP-MS
Not detected
PassSterility
USP <71>
No growth
PassResidual solvents
GC headspace
Within limits
Pass
Every batch on record
View available certificates for previous product lots.
Product information
Research Detail
Research-grade Tirzepatide peptide. A dual GIP/GLP-1 receptor agonist supplied as lyophilized powder for in vitro research. Third-party tested with Certificate of Analysis available.
What is Tirzepatide?
Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist studied for its relationship with incretin signalling, glucose regulation, insulin-response pathways, energy-balance biology, and integrated endocrine communication.
Unlike single-receptor incretin compounds, tirzepatide is designed to activate both glucose-dependent insulinotropic polypeptide (GIP) receptor signalling and glucagon-like peptide-1 (GLP-1) receptor signalling. This dual-pathway activity makes it a compound of interest in laboratory, preclinical, and controlled clinical research focused on metabolic regulation, hormone crosstalk, insulin sensitivity, appetite-related signalling, and systemic energy balance.
Because tirzepatide interacts with two major incretin pathways, it provides researchers with a useful platform for studying how GIP and GLP-1 receptor activity may influence metabolic adaptation, glucose handling, lipid-related pathways, and endocrine signalling integration.
Compound Profile
- Common Research Name
- Tirzepatide
- Development Name
- LY3298176
- Molecular Weight
- ~4,813 g/mol
- Molecular Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- CAS Number
- 2023788-19-2
- PubChem CID
- 156588324
- Peptide Type
- Synthetic acylated dual GIP/GLP-1 receptor agonist
- Purity
- ≥99% (HPLC verified)
Key Areas of Investigation
Tirzepatide has been studied across metabolic, endocrine, cellular, molecular, and systemic research models. The main research interest centres on how dual GIP and GLP-1 receptor signalling may influence glucose regulation, insulin response, metabolic flexibility, and energy-balance pathways.
These findings support tirzepatide as a valuable research compound for studying incretin biology and metabolic signalling, but they do not establish approved therapeutic use.
- Incretin Research: GIP receptor activation, GLP-1 receptor activation, dual incretin signalling, and receptor crosstalk.
- Metabolic Research: Glucose regulation, insulin-response pathways, nutrient utilisation, energy-balance signalling, and metabolic flexibility.
- Endocrine Research: Hormone communication, beta-cell response models, glucagon-related signalling, and integrated endocrine feedback.
- Cellular Research: Receptor activity, intracellular signalling, second-messenger pathways, and metabolic-response mechanisms.
- Body-Composition Research: Appetite-related pathways, adipose-tissue signalling, lipid metabolism, and energy-expenditure models.
- Systemic Research: Cardiometabolic markers, inflammatory-response pathways, hepatic metabolism, and biological resilience in metabolic models.
Scientific references
- Coskun T. et al. (2018)
- Frias J.P. et al. (2018)
- Willard F.S. et al. (2020)
- Rosenstock J. et al. (2021)
- Frias J.P. et al. (2021)
- Jastreboff A.M. et al. (2022)
- Nauck M.A. & D'Alessio D.A. (2022)
- Garvey W.T. et al. (2023)
Technical specifications
Compound Information
Molecular profile
What is Tirzepatide?
Tirzepatide is a dual incretin receptor agonist sequence used widely in metabolic research models. Supplied lyophilised under nitrogen with lot-matched analytical documentation.
- Chemical class
- Dual incretin analogue
- CAS number
- 2023788-19-2
- Molecular weight
- 4813.5 g/mol
- Amino acids
- 39
- Targets
- GIPR / GLP-1R
Storage requirements
Stability information
- −20°C
Lyophilised powder
Sealed, protected from light. Stable 24 months.
- 2–8°C
Reconstituted
Use within 28 days of reconstitution.
- Ambient
In transit
Store sealed at 2–8°C, protected from light
Store sealed at 2–8°C, protected from light
Important research notice
Not for human, veterinary, or food use.
These products are supplied exclusively for laboratory and research purposes and are not intended for human consumption, diagnosis, treatment, cure, or prevention of disease.
Product information and research references are provided for educational and laboratory reference purposes.